Neurocrine Biosciences reported earnings of $ 3.29 per NBIX share on Nov 2, 2026, beating analysts' expectations by
| Report Date | Nov 2, 2026 |
|---|---|
| Forecasted EPS | $ 1.91 |
| Earnings Per Share (Surprise) | $ 3.29 (+$ 1.38) |
| Last Year's EPS | $ 1.27 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Neurocrine Biosciences beat analysts’ expectations 52 times and fell short of expectations 43 time(s). Neurocrine Biosciences reported earnings per share of $ 3.29 in the last report surpassing an estimated EPS of $ 1.91 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 2, 2026 | $ 1.91 | $ 3.29 | $ 2.04 | |
| Jul 30, 2026 | $ 1.65 | $ 1.39 | $ 1.06 | |
| May 5, 2026 | $ 1.22 | $ 1.94 | $ 0.08 | |
| Feb 11, 2026 | $ 1.80 | $ 1.88 | $ 1.00 | |
| Oct 28, 2025 | $ 1.58 | $ 2.04 | $ 1.24 | |
| Jul 30, 2025 | $ 0.98 | $ 1.06 | $ 0.63 | |
| May 5, 2025 | $ 0.535 | $ 0.08 | $ 0.42 | |
| Feb 6, 2025 | $ 1.62 | $ 1.00 | $ 1.44 | |
| Oct 30, 2024 | $ 1.51 | $ 1.24 | $ 0.82 | |
| Aug 1, 2024 | $ 1.05 | $ 0.63 | $ 0.95 | |
| May 1, 2024 | $ 1.01 | $ 0.42 | -$ 0.79 | |
| Feb 7, 2024 | $ 1.15 | $ 1.44 | $ 0.88 | |
| Oct 31, 2023 | $ 0.97 | $ 0.82 | $ 0.69 | |
| Aug 1, 2023 | $ 0.78 | $ 0.95 | -$ 0.18 | |
| May 3, 2023 | $ 0.26 | -$ 0.79 | $ 0.14 | |
| Feb 6, 2023 | $ 1.16 | $ 0.88 | -$ 0.08 | |
| Nov 1, 2022 | $ 0.79 | $ 0.69 | $ 0.23 | |
| Aug 4, 2022 | $ 0.56 | -$ 0.18 | $ 0.43 | |
| May 4, 2022 | $ 0.35 | $ 0.14 | $ 0.33 | |
| Feb 11, 2022 | $ 0.61 | -$ 0.08 | $ 3.58 |
Neurocrine Biosciences’s stock was trading at $ 146.10 on Nov 1, 2026 a day before the last earnings report was released.Following the release of the earnings report, NBIX’s price increased to $ 164.85 on Nov 3, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 2, 2026 | $ 3.29 | $ 146.10 | $ 164.85 | |
| Jul 30, 2026 | $ 1.39 | $ 180.79 | $ 166.80 | |
| May 5, 2026 | $ 1.94 | $ 134.07 | $ 147.02 | |
| Feb 11, 2026 | $ 1.88 | $ 137.65 | $ 123.10 | |
| Oct 28, 2025 | $ 2.04 | $ 148.94 | $ 138.02 | |
| Jul 30, 2025 | $ 1.06 | $ 134.19 | $ 128.23 | |
| May 5, 2025 | $ 0.08 | $ 109.68 | $ 118.92 | |
| Feb 6, 2025 | $ 1.00 | $ 151.20 | $ 122.62 | |
| Oct 30, 2024 | $ 1.24 | $ 116.19 | $ 120.27 | |
| Aug 1, 2024 | $ 0.63 | $ 141.57 | $ 153.14 | |
| May 1, 2024 | $ 0.42 | $ 137.54 | $ 139.83 | |
| Feb 7, 2024 | $ 1.44 | $ 142.96 | $ 134.42 | |
| Oct 31, 2023 | $ 0.82 | $ 107.13 | $ 111.54 | |
| Aug 1, 2023 | $ 0.95 | $ 101.89 | $ 104.14 | |
| May 3, 2023 | -$ 0.79 | $ 103.45 | $ 95.84 | |
| Feb 6, 2023 | $ 0.88 | $ 110.03 | $ 103.82 | |
| Nov 1, 2022 | $ 0.69 | $ 115.12 | $ 122.06 | |
| Aug 4, 2022 | -$ 0.18 | $ 94.06 | $ 104.04 | |
| May 4, 2022 | $ 0.14 | $ 88.70 | $ 85.28 | |
| Feb 11, 2022 | -$ 0.08 | $ 79.60 | $ 86.52 |
Neurocrine Biosciences released its most recent earnings reports in November 2026, July 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Neurocrine Biosciences beat analysts’ expectations during the last earnings period by
